Date:
May 16, 2022
Issue #:
1650
Summary:
The FDA has approved a higher-dose injectable
formulation of the long-acting glucagon-like
peptide-1 (GLP-1) receptor agonist semaglutide
(Ozempic) for treatment of type 2 diabetes in adults.
A single SC injection of the new 8 mg/3 mL
formulation delivers 2 mg of semaglutide.
formulation of the long-acting glucagon-like
peptide-1 (GLP-1) receptor agonist semaglutide
(Ozempic) for treatment of type 2 diabetes in adults.
A single SC injection of the new 8 mg/3 mL
formulation delivers 2 mg of semaglutide.
